R. Zeiser

Futibatinib as a bridge to transplantation and post-transplant maintenance in blast-phase MLN-ZMYM2::FGFR1

Myeloid/lymphoid neoplasms with FGFR1 rearrangement (MLN-FGFR1) are rare, aggressive hematologic malignancies for which allogeneic hematopoietic cell transplantation (allo-HCT) remains the only potentially curative option. Pemigatinib, a reversible FGFR1-3 inhibitor, has substantial activity in chronic phase but lower...

Evaluating the effectiveness of the eHealth-faciLitated SMILe–integrated care model on treatment burden, quality of life and graft-versus-host disease after allogeneic stem cell transplantation: results of two European randomized controlled implementation studies

SMILe–ICM reduced treatment burden and was associated with a lower cumulative incidence of grades II–IV acute GvHD, while HRQoL and chronic GvHD did not differ significantly between groups.

Lung transplantation after allogeneic hematopoietic stem cell transplantation: a study from the Transplant Complications Working Party of the EBMT.

Characterisation of TP53 mutational features and outcomes of acute myeloid leukaemia after allogeneic haematopoietic cell transplantation.

TP53 mutations define a clinically distinct subset of acute myeloid leukaemia (AML) associated with complex cytogenetics and therapy resistance. We performed a retrospective single-centre analysis of 61 consecutive TP53-altered AML patients undergoing first allogeneic haematopoietic cell transplantation (allo-HCT) at t...

Efficacy and safety of the ROCK2-inhibitor belumosudil for chronic GVHD: results from a multicenter retrospective analysis of a large German-Austrian cohort of the belumosudil MAP.

Sitagliptin for Acute Graft-Versus-Host Disease Prevention in Alternative Donor Transplantation: A Randomized Phase III Trial.

PURPOSE This trial evaluated whether the addition of sitagliptin to antithymocyte globulin (ATG)-based prophylaxis reduces the incidence of acute graft-versus-host disease (aGVHD) after alternative donor hematopoietic stem-cell transplantation. METHODS This prospective, multicenter, open-label, randomized trial enrol...

KMT9 drives T cell exclusion and dysfunction by promoting PMN-MDSCs infiltration and ARG1 expression in prostate cancer

Immunotherapy has emerged as a revolutionary therapeutic approach to treat cancer showing remarkable clinical responses. However, its efficacy in solid tumours such as prostate cancer (PCa) remains very limited due to a highly immunosuppressive tumour immune microenvironment (TIME) that hampers cytotoxic T cell infiltr...

Spatial Transcriptomics Reveals a T Cell‐Mediated Microglial Activation Axis of Immune Checkpoint Inhibition‐Related Adverse Events in the Brain

ABSTRACT Immune checkpoint inhibitors (ICIs) targeting CTLA‐4 and PD‐1 have transformed cancer therapy, yet their immune‐related adverse events (irAEs) in various tissues, including the brain, remain poorly defined. ICI perturbs hippocampal‐dependent memory function by derailing neuro‐immune homeostasis and compromisin...

CytoVI: deep generative modeling of antibody-based single cell data.

Antibody-based single-cell technologies, such as flow cytometry, mass cytometry and CITE-seq, have become widely used in clinical diagnostics and basic research; however, their analysis is complicated by technical noise, batch effects, platform differences and restricted antibody panels. Here we present CytoVI, a proba...

Anti-inflammatory approaches in cancer immunotherapy-induced autoimmunity

Cancer immunotherapy, including allogeneic haematopoietic cell transplantation, infusion of chimeric antigen receptor T (CAR-T) cells, bispecific antibodies, and immune checkpoint inhibitors (ICIs), has revolutionised the treatment of cancer. However, therapy resistance and immune-mediated side effects reduce the overa...

Improved progression free survival after axicabtagene ciloleucel compared to tisagenlecleucel, in patients aged >70 years with large B-cell lymphoma.

Outcomes included cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), overall survival (OS), progression-free survival (PFS), relapse incidence (RI), and non-relapse mortality (NRM).

Gp120-Activated Allogeneic Regulatory T cells for Prevention of Graft-versus-Host-Disease - a First-in-Human Trial.

These first clinical data support the feasibility and favorable safety profile of ATreg, a third-party, gp120-activated Treg product requiring no ex vivo expansion, and warrant further evaluation in larger prospective clinical trials.